TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has reported survival benefits in a preclinical study of its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The findings were published in a peer-reviewed article in the journal Cancers.
The study demonstrated that TTX-MC138 accumulated in metastatic bone lesions following systemic administration, reduced expression of microRNA-10b (“miR-10b”), and increased expression of the downstream tumor-suppressor target HOXD10. These molecular effects translated into significant survival benefits compared with controls. Importantly, repeated dosing was well tolerated with no observed systemic toxicity.
These results further support TransCode’s approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology. The company’s lead candidate, TTX-MC138, is designed to treat metastatic tumors that overexpress miR-10b, a well-documented biomarker of metastasis. The positive outcomes in this bone metastasis model suggest potential applicability across additional metastatic disease settings.
“We are encouraged by these findings, which highlight the potential of TTX-MC138 to address metastatic disease, a major cause of cancer-related mortality,” said a company spokesperson. The study adds to a growing body of evidence supporting the therapeutic potential of targeting miR-10b in aggressive cancers.
TransCode Therapeutics is at the forefront of developing RNA-based therapeutics for cancer. Beyond TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The new data from the bone metastasis model could inform the design of future clinical trials and expand the potential patient population that might benefit from this approach.
For more details on the full press release, visit https://ibn.fm/E6gbq. The latest news and updates regarding TransCode Therapeutics are available in the company’s newsroom at https://ibn.fm/RNAZ.
The significance of this study lies in its potential to address bone metastasis, a common and debilitating complication of advanced breast cancer. Current treatments for metastatic disease are often limited, and new therapeutic options are urgently needed. By targeting miR-10b, TTX-MC138 aims to interfere with a key driver of metastasis, offering a novel approach that could improve outcomes for patients with advanced cancers.
These findings also underscore the importance of continued research into RNA-based therapies, which hold promise for precisely targeting disease mechanisms at the molecular level. As TransCode advances its pipeline, the results from this study will likely inform future clinical development strategies and potentially lead to new treatment options for patients with metastatic cancer.
